Shanghai Haohai Biological Technology Co., Ltd.

XSSC:688366 Stock Report

Market Cap: CN¥13.0b

Shanghai Haohai Biological Technology Valuation

Is 688366 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 688366 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 688366 (CN¥62.82) is trading below our estimate of fair value (CN¥289.92)

Significantly Below Fair Value: 688366 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 688366?

Key metric: As 688366 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 688366. This is calculated by dividing 688366's market cap by their current earnings.
What is 688366's PE Ratio?
PE Ratio13.8x
EarningsCN¥430.21m
Market CapCN¥13.04b

Price to Earnings Ratio vs Peers

How does 688366's PE Ratio compare to its peers?

The above table shows the PE ratio for 688366 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average25.8x
688336 Sunshine Guojian Pharmaceutical (Shanghai)
38.8x-11.7%CN¥13.8b
688276 Changchun BCHT Biotechnology
26.3x39.3%CN¥10.8b
300009 Anhui Anke Biotechnology (Group)
19.1x16.7%CN¥14.8b
000403 Pacific Shuanglin Bio-pharmacy
18.8x12.7%CN¥15.5b
688366 Shanghai Haohai Biological Technology
13.8x16.8%CN¥14.0b

Price-To-Earnings vs Peers: 688366 is good value based on its Price-To-Earnings Ratio (13.8x) compared to the peer average (25.4x).

Price to Earnings Ratio vs Industry

How does 688366's PE Ratio compare vs other companies in the CN Biotechs Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
No more companies available in this PE range
688366 13.8xIndustry Avg. 35.6xNo. of Companies6PE020406080100+
0 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 688366 is good value based on its Price-To-Earnings Ratio (13.8x) compared to the CN Biotechs industry average (36.3x).

Price to Earnings Ratio vs Fair Ratio

What is 688366's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

688366 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio13.8x
Fair PE Ratio25.7x

Price-To-Earnings vs Fair Ratio: 688366 is good value based on its Price-To-Earnings Ratio (13.8x) compared to the estimated Fair Price-To-Earnings Ratio (25.7x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Hunan Jiudian Pharmaceutical

CN¥12.2b

Researches, develops, produces, and sells pharmaceutical products in China and internationally.

300705

CN¥24.71

7D

-0.2%

1Y

5.1%

China Resources Double-Crane PharmaceuticalLtd

CN¥21.4b

China Resources Double-Crane Pharmaceutical Co.,Ltd.

600062

CN¥20.87

7D

-5.5%

1Y

11.1%

Hunan Jiudian Pharmaceutical

CN¥12.2b

Researches, develops, produces, and sells pharmaceutical products in China and internationally.

300705

CN¥24.71

7D

-0.2%

1Y

5.1%